JP2024038524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038524A5 JP2024038524A5 JP2024016033A JP2024016033A JP2024038524A5 JP 2024038524 A5 JP2024038524 A5 JP 2024038524A5 JP 2024016033 A JP2024016033 A JP 2024016033A JP 2024016033 A JP2024016033 A JP 2024016033A JP 2024038524 A5 JP2024038524 A5 JP 2024038524A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfate
- peaks
- dihydrogen phosphate
- disease
- sulfate form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025105737A JP2025131907A (ja) | 2018-04-12 | 2025-06-23 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2025171096A JP2026004574A (ja) | 2018-04-12 | 2025-10-09 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656435P | 2018-04-12 | 2018-04-12 | |
| US62/656,435 | 2018-04-12 | ||
| PCT/US2019/027369 WO2019200345A1 (en) | 2018-04-12 | 2019-04-12 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
| JP2020555811A JP7532718B2 (ja) | 2018-04-12 | 2019-04-12 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555811A Division JP7532718B2 (ja) | 2018-04-12 | 2019-04-12 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105737A Division JP2025131907A (ja) | 2018-04-12 | 2025-06-23 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2025171096A Division JP2026004574A (ja) | 2018-04-12 | 2025-10-09 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024038524A JP2024038524A (ja) | 2024-03-19 |
| JP2024038524A5 true JP2024038524A5 (cg-RX-API-DMAC7.html) | 2025-01-21 |
| JP7758768B2 JP7758768B2 (ja) | 2025-10-22 |
Family
ID=68163817
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555811A Active JP7532718B2 (ja) | 2018-04-12 | 2019-04-12 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2024016033A Active JP7758768B2 (ja) | 2018-04-12 | 2024-02-05 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2025105737A Pending JP2025131907A (ja) | 2018-04-12 | 2025-06-23 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2025171096A Pending JP2026004574A (ja) | 2018-04-12 | 2025-10-09 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555811A Active JP7532718B2 (ja) | 2018-04-12 | 2019-04-12 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105737A Pending JP2025131907A (ja) | 2018-04-12 | 2025-06-23 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
| JP2025171096A Pending JP2026004574A (ja) | 2018-04-12 | 2025-10-09 | 物質のa2-73結晶多形組成物およびそれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11498908B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773531A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7532718B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112105349A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019253028B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3096671C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019200345A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
| WO2021158586A1 (en) | 2020-02-04 | 2021-08-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of blarcamesine salts |
| JP2025514292A (ja) * | 2022-04-29 | 2025-05-02 | ▲蘇▼州科睿思制▲葯▼有限公司 | 塩酸ブラルカメシンの結晶形、その調製方法およびその使用 |
| US12018005B1 (en) | 2023-07-25 | 2024-06-25 | Egis Gyógyszergyár Zrt. | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| AU2011267474B2 (en) * | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| WO2014159814A1 (en) * | 2013-03-13 | 2014-10-02 | Patricia Oliver | Formulations and tablets for treatment or prevention of neurological disorders |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
| AU2016248376B2 (en) * | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| MX388953B (es) * | 2015-05-20 | 2025-03-20 | Ube Industries | Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo. |
| EP4616852A3 (en) * | 2015-07-22 | 2025-10-22 | Anavex Life Sciences Corp. | Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions |
| US11617734B2 (en) * | 2015-07-22 | 2023-04-04 | Anavex Life Sciences Corp. | Enantiomers of A2-73, analogues, and sigma agonist activity |
| JP6866379B2 (ja) * | 2016-01-26 | 2021-04-28 | アナベックス ライフ サイエンシズ コーポレイション | 神経発達障害療法 |
| WO2017172784A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CN111315375A (zh) * | 2017-06-14 | 2020-06-19 | 阿纳韦克斯生命科学公司 | 用于治疗阿尔茨海默病的anavex2-73 |
| AU2018375667B2 (en) * | 2017-11-28 | 2023-03-02 | Anavex Life Sciences Corp. | Sigma-1 receptor agonist systolic blood pressure therapy |
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
-
2019
- 2019-04-12 CN CN201980031851.3A patent/CN112105349A/zh active Pending
- 2019-04-12 CA CA3096671A patent/CA3096671C/en active Active
- 2019-04-12 CA CA3256071A patent/CA3256071A1/en active Pending
- 2019-04-12 EP EP19785595.0A patent/EP3773531A4/en active Pending
- 2019-04-12 US US17/046,929 patent/US11498908B2/en active Active
- 2019-04-12 WO PCT/US2019/027369 patent/WO2019200345A1/en not_active Ceased
- 2019-04-12 JP JP2020555811A patent/JP7532718B2/ja active Active
- 2019-04-12 AU AU2019253028A patent/AU2019253028B2/en active Active
-
2022
- 2022-11-01 US US17/978,818 patent/US12180174B2/en active Active
-
2024
- 2024-02-05 JP JP2024016033A patent/JP7758768B2/ja active Active
- 2024-08-02 AU AU2024205423A patent/AU2024205423B2/en active Active
- 2024-12-17 US US18/984,748 patent/US20250115566A1/en active Pending
-
2025
- 2025-06-23 JP JP2025105737A patent/JP2025131907A/ja active Pending
- 2025-10-09 JP JP2025171096A patent/JP2026004574A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI689490B (zh) | 用於治療纖維化之經取代之芳族化合物及相關方法 | |
| JP2024540183A5 (cg-RX-API-DMAC7.html) | ||
| JP2003507438A5 (cg-RX-API-DMAC7.html) | ||
| US8426388B2 (en) | Prodrugs of HIV protease inhibitors | |
| TW200811167A (en) | Modulators of pharmacokinetic properties of therapeutics | |
| JP2022543244A5 (cg-RX-API-DMAC7.html) | ||
| JP2023552700A5 (cg-RX-API-DMAC7.html) | ||
| JP6959246B2 (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| JP2025118775A5 (cg-RX-API-DMAC7.html) | ||
| JP2004026678A (ja) | 2型糖尿病治療剤 | |
| JP2002544227A5 (cg-RX-API-DMAC7.html) | ||
| WO2002034245A2 (en) | Use of tolterodine to treat asthma | |
| JP2023505587A (ja) | 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP2023505598A (ja) | 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP2022501364A5 (cg-RX-API-DMAC7.html) | ||
| JP2023538419A5 (cg-RX-API-DMAC7.html) | ||
| CN111909204B (zh) | 一种替诺福韦双苯丙酸酯基氨基磷酸酯化合物及其药物组合物和用途 | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| WO2024192149A3 (en) | Method of treating enterovirus in chronic obstructive pulmonary disease patients | |
| US12344619B2 (en) | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof | |
| CN102659570A (zh) | 二氟非诺贝特酸及其在药学上可接受的盐,以及它们的制备方法和应用 | |
| JP2023512023A5 (cg-RX-API-DMAC7.html) | ||
| JP2024541770A5 (cg-RX-API-DMAC7.html) | ||
| AU2024203992B2 (en) | Prophylactic or therapeutic agent for porphyria | |
| JP2000219626A (ja) | ケロイドおよび/または肥厚性瘢痕の治療剤 |